| 产品编号 | bs-1310R |
| 英文名称 | Rabbit Anti-Integrin Alpha V + Beta 3 (CD51+CD61) antibody |
| 中文名称 | 整合素αVβ3抗体 |
| 别 名 | CIntegrin alpha 5 beta 3; D51 + CD61; CD51; CD61; GP3A; GPIIIa; integrin alpha v; integrin beta 3; intregrin alpha v beta 3; ITGAV; ITGB3; Platelet membrane glycoprotein IIIa; Vitronectin receptor alpha subunit; VNRA; Antigen identified by monoclonal antibody L230; CD51 antigen; CD61 antigen; DKFZp686A08142; Integrin alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); integrin alpha v; Integrin beta 3 (platelet glycoprotein IIIa, antigen CD61); Integrin beta chain beta 3; intregrin alpha v beta 3; ITGAV; MSK8; Platelet glycoprotein IIIa; Platelet membrane glycoprotein IIIa; Vitronectin receptor alpha subunit; Vitronectin receptor subunit alpha; avb3. |
 |
Specific References (36) | bs-1310R has been referenced in 36 publications.
|
| 研究领域 | 细胞生物 免疫学 信号转导 干细胞 细胞粘附分子 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human,Mouse,Rat |
| 产品应用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=1μg/Test,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 细胞定位 | 细胞膜 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Integrin Alpha V + Beta 3 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. They are known to participate in cell adhesion as well as cell-surface mediated signalling. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. CD51 encodes integrin alpha chain V. The I-domain containing integrin alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. The CD61 protein product is the integrin beta chain beta 3. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrin alpha V/beta 3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase 2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha V/beta 3 recognizes the sequence R-G-D in a wide array of ligands. The alpha V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase 2, osteopontin, osteomodulin, prothrombin, thrombospondin and von Willebrand factor. They recognize the sequence R-G-D in a wide array of ligands. Subcellular Location: Cell Membrane; single-pass type I membrane protein. SWISS: P06756 Gene ID: 3685 Database links: Entrez Gene: 3685 Human SwissProt: P06756 Human |
| 产品图片 |
Sample: HUVEC (human)Cell Lysate at 40 ug
Primary: Anti- Integrin Alpha V + Beta 3 (CD51+CD61) (bs-1310R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 116 kD
Observed band size: 120 kD
Tissue/cell: Human laryngeal tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-Integrin Alpha V + Beta 3 (CD51 + CD61) Polyclonal Antibody, Unconjugated(bs-1310R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: Human lung cancer tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-Integrin Alpha V + Beta 3 (CD51 + CD61) Polyclonal Antibody, Unconjugated(bs-1310R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-Integrin Alpha V + Beta 3(CD51+CD61) Polyclonal Antibody, Unconjugated(bs-1310R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Blank control: U937(blue). Primary Antibody: Rabbit Anti-Integrin Alpha V + Beta 3 (CD51+CD61) antibody(bs-1310R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions ); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Protocol
The cells were fixed with 2% paraformaldehyde (10 min). Primary antibody (bs-1310R, 1μg /1x10^6 cells) were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 10% goat serum (15 min) to block non-specific protein-protein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.
Cell: MCF-7
Concentration:1:100
Host/Isotype:Rabbit/IgG
Flow cytometric analysis of Rabbit IgG isotype control (Cat#: bs-1310R) on MCF-7(green) compared with control in the absence of primary antibody (blue) followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG(H+L) secondary antibody .
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
